A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Primary Outcome Measures  :

1. Number of Participants with Dose Limiting Toxicities (DLTs) [ Time Frame: 12 months ]
   
2. Number of Participants with Treatment-emergent Adverse Events (TEAEs) [ Time Frame: 12 months ]
   
3. Number of Participants with Treatment-related Adverse Events [ Time Frame: 12 months ]
   
4. Number of Participants with Clinically Significant Changes in Vital Signs. [ Time Frame: 12 months ]
   
5. Number of Participants with Clinically Significant Changes of ECG Measurement [ Time Frame: 12 months ]
   
6. Number of Participants with Clinically Significant Laboratory Values [ Time Frame: 12 months ]
   

Secondary Outcome Measures  :

1. Maximum Plasma Concentration (Cmax) [ Time Frame: 12 months ]
   
2. Time to Maximum Plasma Concentration (Tmax) [ Time Frame: 12 months ]
   
3. Area Under the Plasma Concentration-time Curve (AUC) [ Time Frame: 12 months ]
   
4. Disease Control Rate [ Time Frame: 12 months ]
   
5. Duration of Response [ Time Frame: 12 Months ]
   
6. Progression-free Survival [ Time Frame: 12 months ]
   
7. Duration of Stable Disease [ Time Frame: 12 Months ]
   
8. Objective Response Rate [ Time Frame: 12 months ]
   
9. Time to Response [ Time Frame: 12 Months ]
   
10. Overall Survival [ Time Frame: 12 Months ]

Inclusion Criteria:

• Men or women greater than or equal to 18 years old.
• Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing.

Exclusion Criteria:

• Primary brain tumor.
• Spinal cord compression, or untreated, or symptomatic, or active brain metastases, or leptomeningeal disease from non-brain tumors.
• Myocardial infarction within 6 months of study day 1.
• Gastrointestinal (GI) tract disease causing the inability to take oral medication.